title: Chemotherapy-induced damage to ovary: mechanisms and clinical impact.
abstract: Cancer is a major public health problem around the world. Currently, about 5% of women diagnosed with cancer are of reproductive age. These young survivors may face compromised fertility. The effects of chemotherapeutic agents on ovarian reserve and its clinical consequences are generally inferred from a variety of surrogate markers of ovarian reserve, all aiming to provide prognostic information on fertility or the likelihood of success of infertility treatment. Until recently, the mechanisms that are responsible for chemotherapy-induced ovarian damage were not fully elucidated. The understanding of these mechanisms may lead to targeted treatments to preserve fertility. In this manuscript, we will review the current knowledge on the mechanism of ovarian damage and clinical impact of chemotherapy agents on fertility.
authors.affiliation: Innovation Institute for Fertility Preservation & In vitro Fertilization, New York, NY, USA.|Laboratory of Molecular Reproduction & Fertility Preservation, Obstetrics & Gynecology, New York Medical College, Valhalla, NY, USA.|Division of Reproductive Medicine, Department of Gynecology & Obstetrics, Faculty of Medicine of Ribeirão Preto, University of São Paulo, Ribeirão Preto, SP, Brazil.
authors.forename: Giuliano
authors.initials: G
authors.lastname: Bedoschi
authors.affiliation: Division of Reproductive Medicine, Department of Gynecology & Obstetrics, Faculty of Medicine of Ribeirão Preto, University of São Paulo, Ribeirão Preto, SP, Brazil.
authors.forename: Paula Andrea
authors.initials: PA
authors.lastname: Navarro
authors.affiliation: Innovation Institute for Fertility Preservation & In vitro Fertilization, New York, NY, USA.|Laboratory of Molecular Reproduction & Fertility Preservation, Obstetrics & Gynecology, New York Medical College, Valhalla, NY, USA.
authors.forename: Kutluk
authors.initials: K
authors.lastname: Oktay
mesh_terms: D000375:Aging; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D015415:Biomarkers; D005260:Female; D005298:Fertility; D059247:Fertility Preservation; D006801:Humans; D007247:Infertility, Female / Q000175:diagnosis / Q000209:etiology / Q000628:therapy; D009369:Neoplasms / Q000150:complications / Q000188:drug therapy; D006080:Ovarian Follicle / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D065851:Ovarian Reserve / Q000187:drug effects*; D010053:Ovary / Q000187:drug effects* / Q000473:pathology / Q000503:physiopathology; D012306:Risk
chemical_list: D000970:Antineoplastic Agents; D015415:Biomarkers
keywords: anti-Mullerian hormone; antral follicle count; chemotherapy; fertility preservation; follicle-stimulating hormone; ovarian aging; ovarian damage; ovarian reserve